Valuation : Sanofi

Market Cap 91.36B 106B 85.96B 78.53B 147B 10,025B 147B 1,016B 394B 5,143B 399B 390B 16,570B P/E 2026 *
12.1x
P/E 2027 * 10.6x
Enterprise Value 103B 119B 96.74B 88.37B 165B 11,282B 166B 1,143B 444B 5,788B 449B 439B 18,647B EV / Sales 2026 *
2.16x
EV / Sales 2027 * 1.96x
Free-Float
88.34%
Yield 2026 *
5.58%
Yield 2027 * 5.9%
Manager TitleAgeSince
Chief Executive Officer 65 01/05/2026
Director of Finance/CFO 64 01/04/2024
Chief Tech/Sci/R&D Officer - 01/09/2026
Director TitleAgeSince
Director/Board Member 61 30/04/2019
Director/Board Member 57 28/04/2020
Director/Board Member 65 28/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 106B
-0.88%-2.15%+54.71%+106.31% 1,024B
-1.15%+2.68%+53.97%+71.50% 663B
-1.44%+0.38%+20.40%+73.05% 453B
+0.14%-0.47%+29.49%+38.56% 352B
-1.33%+4.72%+24.69%+45.55% 304B
-1.15%+0.30%-1.49%+12.31% 252B
-1.55%+1.11%+56.10%+70.32% 236B
-0.88%+1.15%-17.09%-54.39% 206B
-0.15%+3.65%+33.90%+96.99% 187B
Average -0.89%+1.09%+28.30%+51.13% 408.71B
Weighted average by Cap. -1.07%+0.55%+36.62%+66.22%

Financials

2026 *2027 *
Net sales 47.66B 55.38B 44.84B 40.96B 76.62B 5,229B 76.83B 530B 206B 2,683B 208B 203B 8,643B 50.76B 58.98B 47.75B 43.62B 81.61B 5,569B 81.83B 564B 219B 2,857B 221B 217B 9,205B
Net income 7.63B 8.87B 7.18B 6.56B 12.27B 837B 12.3B 84.82B 32.91B 429B 33.29B 32.57B 1,384B 8.93B 10.38B 8.4B 7.68B 14.36B 980B 14.4B 99.28B 38.53B 503B 38.97B 38.12B 1,619B
Net Debt 11.46B 13.31B 10.78B 9.85B 18.42B 1,257B 18.47B 127B 49.43B 645B 50B 48.91B 2,078B 8.3B 9.65B 7.81B 7.14B 13.35B 911B 13.39B 92.32B 35.82B 467B 36.24B 35.45B 1,506B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
76.26EUR
Average target price
94.28EUR
Spread / Average Target
+23.63%

Quarterly revenue - Rate of surprise